Guggenheim Capital LLC Sells 679 Shares of argenx SE (NASDAQ:ARGX)

Guggenheim Capital LLC lessened its holdings in argenx SE (NASDAQ:ARGX) by 16.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,328 shares of the company’s stock after selling 679 shares during the quarter. Guggenheim Capital LLC’s holdings in argenx were worth $2,047,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in ARGX. Whipplewood Advisors LLC acquired a new position in argenx in the 4th quarter valued at approximately $37,000. Global Retirement Partners LLC increased its holdings in argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after purchasing an additional 48 shares during the period. FIL Ltd bought a new position in argenx during the 4th quarter worth $38,000. Jones Financial Companies Lllp lifted its holdings in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after buying an additional 61 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. grew its position in shares of argenx by 78.6% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company’s stock valued at $46,000 after buying an additional 33 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Stock Up 1.5 %

Shares of argenx stock opened at $596.20 on Monday. The business has a 50 day moving average price of $602.53 and a 200-day moving average price of $606.37. argenx SE has a 52 week low of $352.77 and a 52 week high of $678.21. The company has a market cap of $36.23 billion, a PE ratio of -677.50 and a beta of 0.60.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, research analysts anticipate that argenx SE will post 3.13 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on ARGX. Wells Fargo & Company lifted their price objective on argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Truist Financial restated a “buy” rating and issued a $700.00 price target (up previously from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Wedbush reiterated an “outperform” rating and set a $715.00 price objective on shares of argenx in a research report on Friday, April 11th. Robert W. Baird upped their price target on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research report on Tuesday, March 4th. Finally, Citigroup lifted their price objective on argenx from $681.00 to $796.00 and gave the stock a “buy” rating in a research report on Thursday. Three investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $699.28.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.